Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company that intends to change its name to ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Behind-the-knee pain could be due to muscle strain or arthritis—or something far more serious. Orthopedic experts say these ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Platelet count is an essential diagnostic tool that measures the number of platelets per blood microliter (mcL). It can help doctors identify potential health complications related to wound ...

However, new treatment options are emerging through ongoing research. In B-PLL, immature forms of B-lymphocytes, called prolymphocytes, divide and multiply rapidly in the bone marrow and blood.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to ...

Systemic lupus erythematosus (SLE) often presents with neuropsychiatric (NP) involvement, including cognitive impairment and depression. Past magnetic resonance imaging (MRI) research in SLE patients ...